Kidney Disease in Patients Receiving Immune Checkpoint Inhibitor Therapy
- Study HIC#:2000033212
- Last Updated:08/27/2024
The overall goal of this project is to provide clinicians with non-invasive acute kidney injury (AKI) biomarkers in patients who develop kidney injury while on Immune Checkpoint Inhibitor therapy and to understand the impact of early acute kidney injury (AKI)/acute interstitial nephritis (AIN) and other predictors on long-term chronic kidney disease risk in cancer survivors. Patients can access the study survey here: https://yalesurvey.ca1.qualtrics.com/jfe/form/SV_09xx6hfw9evWeTY
Contact Us
For more information about this study, including how to volunteer, contact:
Melissa Shaw
- Phone Number: 1-203-785-2107
Help Us Discover!
You can help our team find trials you might be eligible for by creating a volunteer profile in MyChart. To get started, create a volunteer profile, or contact helpusdiscover@yale.edu, or call +18779788343 for more information.
Eligibility Criteria
Eligibility Criteria:
- Male or female ≥18 years of age at enrollment
- Receiving ICI therapy ≤12 months at Smilow Cancer Hospital
- Decrease in kidney function indicative of acute kidney injury defined as 50% increase in serum creatinine from pre-therapy baseline (for AKI) and absence of AKI in non-AKI group
Exclusion Criteria:
- Receiving corticosteroids (>10mg/day prednisone equivalent) or another immunosuppressive therapy
- End-stage kidney disease
- Known pregnant at time of enrollment
- Additional vulnerable individuals (incarcerated, institutionalized, or otherwise unable to participate in the study)
- Inability of subject or subject’s proxy to provide informed consent
